Document Type

Article

Publication Date

3-20-2022

Publication Title

Cancer cell international [electronic resource]

Keywords

JGM

JAX Source

Cancer Cell Int 2022 Mar 20; 22(1):130

Volume

22

Issue

1

First Page

130

Last Page

130

ISSN

1475-2867

PMID

35307036

DOI

https://doi.org/10.1186/s12935-022-02524-y

Abstract

Cancer cells must rewire cellular metabolism to satisfy the unbridled proliferation, and metabolic reprogramming provides not only the advantage for cancer cell proliferation but also new targets for cancer treatment. However, the plasticity of the metabolic pathways makes them very difficult to target. Deubiquitylating enzymes (DUBs) are proteases that cleave ubiquitin from the substrate proteins and process ubiquitin precursors. While the molecular mechanisms are not fully understood, many DUBs have been shown to be involved in tumorigenesis and progression via controlling the dysregulated cancer metabolism, and consequently recognized as potential drug targets for cancer treatment. In this article, we summarized the significant progress in understanding the key roles of DUBs in cancer cell metabolic rewiring and the opportunities for the application of DUBs inhibitors in cancer treatment, intending to provide potential implications for both research purpose and clinical applications.

Comments

This is an Open Access article distributed under the terms of the Creative Commons Attribution License

Download

Share

COinS